ArticleAdvanced pharmaceutical bulletin2026
The RNA-Binding Proteins Promote Resistance of Microglial Cells to Hypoxia.
Article in Advanced pharmaceutical bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Microglial cells play a crucial role in responding to brain hypoxia. This study aimed to evaluate the effect of RNA-binding proteins (RBPs) on the resistance of microglial cells to hypoxia. Methods: Newborn rats were subjected to hypoxia under four conditions: hypoxia (H), one week after hypoxia induction (H1), control (C), and control one week after hypoxia induction (C1). Microglial cells were isolated and cultured, and exosomes were extracted from brain samples of healthy newborn rats of C1 group. RBPs were extracted from the aforementioned groups and transferred into the microglial cells using exosomes from the C1 group. Cell viability, expression of specific RBP genes, and innate immune factors were evaluated in the studied groups. Additionally, exosomes containing RBPs were injected into the hypoxic rats to investigate behavioral changes in-vivo. Results: The treatment of microglial cells with C1 exosomes elevated the viability rate. The RBP-H proteins significantly elevated the expression of the CPE, HIF-1α, PDI, and VEGF-A genes. Improvements in anti-protease activity, along with decreases in lysozyme and myeloperoxidase activity, were observed in hypoxic microglial cells following treatment with RBP-H and exosomes containing RBP-H. In vivo evaluations revealed that the hypoxic group treated with exosome loading with RBP-H exhibited significant improvements in recognition and balance maintenance. Conclusion: The RBPs may be considered a promising option for further studies in the treatment of brain disorders resulting from hypoxia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.